Facebook Twitter Newsletter Linkedin RSS

Portail de la presse

MorphoSys AG Announces Expanded Agreement With Bristol-Myers Squibb on Use of HuCAL GOLD(R)

Press and analyst contact
Andrew Lloyd & Associates
Andrew Lloyd / Guillaume Zeller
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser. / Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
33 1 56 54 07 00

MorphoSys AG contact
Dave Lemus
Chief Financial Officer
Tel: +49 (0) 89 / 899 27-439
Fax: +49 (0) 89 / 899 27-5439
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
Dr. Claudia Gutjahr-Löser
Director Corporate Communications
Tel: +49 (0) 89 / 899 27-122
Fax: +49 (0) 89 / 899 27-5122
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
Mario Brkulj
PR Specialist
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.


MorphoSys AG Announces Expanded Agreement With Bristol-Myers Squibb on Use of HuCAL GOLD(R)

Martinsried/Munich, January 26, 2005 - MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today a further expansion of its existing license agreement with Bristol-Myers Squibb Company (NYSE: BMY). Under the amended agreement, MorphoSys grants Bristol-Myers Squibb access to its HuCAL GOLD(R) library for use in Bristol-Myers Squibb's pharmaceutical discovery programs for target characterization and validation, as well as for therapeutic and diagnostic antibody product development.  Financial details were not disclosed.

Prior to the most recent expansion of the existing license agreement, Bristol-Myers Squibb had a non-exclusive license to use prior versions of MorphoSys' HuCAL(R) library and the AutoCALTM system, which is MorphoSys' established system for fully automated high-throughput antibody generation, installed at one of Bristol-Myers Squibb's facilities in the U.S.
Bristol-Myers Squibb currently applies MorphoSys' proprietary antibody technology in its pharmaceutical discovery programs for target characterization and validation.  In addition, Bristol-Myers Squibb has an option to further develop promising antibody candidates arising from these programs as therapeutics and diagnostics.
"Bristol-Myers Squibb has now decided to upgrade to the most advanced version of our antibody library, HuCAL GOLD(R)," commented Dr. Simon Moroney, Chief Executive Officer, MorphoSys AG. "We are delighted that Bristol-Myers Squibb continues to value our expertise in antibody development, as well as in supporting its target characterization and validation programs."

About MorphoSys:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL') technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Basel, Switzerland), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). Additionally, MorphoSys is active in the antibody research market through its Antibodies by Design business unit. Antibodies by Design was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005. For further information please visit the corporate website at: http://www.morphosys.com/.

About Bristol-Myers Squibb:
Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb on the World Wide Web at www.bms.com.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.
--
Stéphanie CHANE CHICK TE

ANDREW LLOYD & ASSOCIATES
http://www.ala.com

55 rue Boissonade
75014 PARIS
FRANCE

Tel  : +33-1 56 54 07 00
Fax : +33-1 56 54 07 01

Brighton Business Centre
95 Ditchling Road
Brighton BN 1 4ST
ENGLAND

Tel:  +44-1273 675100
Fax: +44-1273 675400

email : Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

INTERNATIONAL TECHNOLOGY MARKETS            STRATEGY & COMMUNICATIONS